{"id":"nitrofurantoin","rwe":[{"pmid":"41892484","year":"2026","title":"Antimicrobial Resistance and ESBL-Associated Predictors Among Uropathogens: A 2019-2024 Isolate-Level Study.","finding":"","journal":"Antibiotics (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"41892400","year":"2026","title":"Evidentiary Standards for Newly Approved Antibiotics for Uncomplicated Urinary Tract Infections.","finding":"","journal":"Antibiotics (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"41886421","year":"2026","title":"Urinary tract infections, risk factors and antimicrobial resistance patterns in heart failure patients on sodium-glucose transporter 2 inhibitors: Evidence from Jakaya Kikwete Cardiac Institute in Tanzania.","finding":"","journal":"PloS one","studyType":"Clinical Study"},{"pmid":"41885022","year":"2026","title":"Solid Phase Microwave Assisted Synthesis N,S-GQDs as Nano-photocatalyst for Efficient Degradation of Nitrofurantoin and Methylene Blue under Visible Light: Comparative Studies, Mechanism Insight, and Extended Scope.","finding":"","journal":"Langmuir : the ACS journal of surfaces and colloids","studyType":"Clinical Study"},{"pmid":"41884811","year":"2026","title":"Environmental triggers of autoimmune hepatitis: a clinical perspective from Yemeni patients.","finding":"","journal":"Frontiers in immunology","studyType":"Clinical Study"}],"_fda":{"id":"14c9efac-c0b1-7afe-e063-6294a90a39e4","set_id":"04af8b73-7e15-7da8-e063-6294a90af284","openfda":{"nui":["N0000175494","M0014892"],"unii":["927AH8112L"],"route":["ORAL"],"rxcui":["311989"],"spl_id":["14c9efac-c0b1-7afe-e063-6294a90a39e4"],"brand_name":["Nitrofurantoin"],"spl_set_id":["04af8b73-7e15-7da8-e063-6294a90af284"],"package_ndc":["72603-176-01"],"product_ndc":["72603-176"],"generic_name":["NITROFURANTOIN"],"product_type":["HUMAN PRESCRIPTION DRUG"],"pharm_class_cs":["Nitrofurans [CS]"],"substance_name":["NITROFURANTOIN"],"pharm_class_epc":["Nitrofuran Antibacterial [EPC]"],"manufacturer_name":["NorthStar Rx LLC"],"application_number":["ANDA216385"],"is_original_packager":[true]},"version":"2","pregnancy":["8.1 Pregnancy Risk Summary Nitrofurantoin is contraindicated in pregnant women at term (38 weeks to 42 weeks gestation), during labor and delivery, or when the onset of labor is imminent because of the possibility of hemolytic anemia in the infant (see Clinical Considerations). Published epidemiological studies, including cohort studies and case control studies, have reported inconsistent findings related to nitrofurantoin use during the first trimester and risk of major birth defects. These studies cannot definitively establish the presence or absence of risk due to several methodological limitations. The limited number of epidemiological studies available have not identified drug-associated risks of major birth defects, miscarriage or other adverse maternal or fetal outcomes. In animal reproduction studies, no fetotoxicity was observed when nitrofurantoin was administered orally to pregnant rats and rabbits, during organogenesis, at up to 6 times the recommended human dose (see Data ). The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Clinical Considerations Fetal/Neonatal Adverse Reactions Nitrofurantoin is not recommended in pregnant women at term (38 weeks to 42 weeks gestation), during labor and delivery, or when the onset of labor is imminent because of the possibility of hemolytic anemia due to immature erythrocyte enzyme systems (glutathione instability) [see Contraindications (4) and Warnings and Precautions (5.4)]. Data Animal Data Several reproduction studies have been performed in rabbits and rats at doses up to six times the human dose and have revealed no harm to the fetus due to nitrofurantoin. In a single published study conducted in mice at 68 times the human dose (based on mg/kg administered to the dam), growth retardation and a low incidence of minor and common malformations were observed. However, at 25 times the human dose, fetal malformations were not observed. Nitrofurantoin has been shown in one published transplacental carcinogenicity study to induce lung papillary adenomas in the F1 generation mice at doses 19 times the human dose on a mg/kg basis. The relationship of this finding to potential human carcinogenesis is presently unknown."],"overdosage":["10 OVERDOSAGE Incidents of acute overdosage of nitrofurantoin have resulted in symptoms such as vomiting. Induction of emesis is recommended. There is no specific antidote, but a high fluid intake should be maintained to promote urinary excretion of the drug. Nitrofurantoin is dialyzable."],"description":["11 DESCRIPTION Nitrofurantoin Oral Suspension, USP contains nitrofurantoin, a synthetic nitrofuran antibacterial agent specific for urinary tract infections. The chemical name is 1-[[(5-nitro-2-furanyl)methylene]amino]-2,4­imidazolidinedione monohydrate. The molecular formula is C8H6N4O5·H2O and the molecular weight is 256.17. The structural formula is: Nitrofurantoin is a stable, yellow, crystalline compound. Nitrofurantoin Oral Suspension, USP is available as a lemon-yellow liquid with cherry flavor, free from extraneous particles for oral administration containing 25 mg/5 mL of nitrofurantoin. Nitrofurantoin Oral Suspension, USP also contains the following inactive ingredients: citric acid, artificial cherry flavor, glycerin, methylparaben, propylparaben, purified water, sodium citrate, sucralose, simethicone emulsion, and xanthan gum. structure"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING How Supplied Nitrofurantoin Oral Suspension, USP 25 mg/5 mL is available in: 230 mL PET amber bottle NDC 72603-176-01 Storage and Handling Avoid exposure to strong light which may darken the drug. It is stable when stored between 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [See USP Controlled Room Temperature]. Protect from freezing. Shake vigorously. Dispense in tight, light-resistant, plastic (PET) or glass container. Use within 30 days. Keep out of reach of children."],"microbiology":["12.4 Microbiology Mechanism of Action Nitrofurantoin is reduced by a wide range of enzymes including bacterial flavoproteins to reactive intermediates which are damaging to macromolecules such as DNA and proteins. Resistance Nitrofurantoin is not active against most strains of Proteus species or Serratia species. It has no activity against Pseudomonas species. Although cross-resistance with other antibacterials may occur, cross resistance with sulfonamides has not been observed. Interaction with Other Antibacterials Antagonism has been demonstrated in vitro between nitrofurantoin and quinolones. Antibacterial Activity Nitrofurantoin has been shown to be active against most of the following bacteria both in vitro and in clinical infections: Aerobic bacteria Gram-positive bacteria Staphylococcus aureus Enterococcus species Gram-negative bacteria Escherichia coli Enterobacter species Klebsiella species The following in vitro data are available, but their clinical significance is unknown. Nitrofurantoin exhibits in vitro activity against the following bacteria; however, the safety and efficacy of nitrofurantoin in treating clinical infections due to these bacteria have not been established in adequate and well-controlled clinical trials. Aerobic bacteria Gram-positive bacteria Coagulase-negative staphylococci (including Staphylococcus epidermidis and Staphylococcus saprophyticus ) Streptococcus agalactiae Viridans group streptococci Gram-negative bacteria Citrobacter koseri Citrobacter freundii Klebsiella oxytoca Susceptibility Testing For specific information regarding susceptibility test interpretive criteria, and associated test methods and quality control standards recognized by FDA for this drug, please see: http://www.fda.gov/STIC ."],"pediatric_use":["8.4 Pediatric Use Nitrofurantoin is contraindicated in pediatric patients younger than 1 month of age because of the possibility of hemolytic anemia due to immature erythrocyte enzyme systems (glutathione instability). [see Contraindications (4) and Warnings and Precautions (5.4)]. The safety and effectiveness of nitrofurantoin in pediatric patients aged 1 month of age and older for the treatment of urinary tract infections have been established."],"effective_time":"20240329","pharmacodynamics":["12.2 Pharmacodynamics Pharmacodynamic effects of nitrofurantoin are unknown."],"pharmacokinetics":["12.3 Pharmacokinetics Absorption Orally administered nitrofurantoin is readily absorbed. Blood concentrations at therapeutic dosage are usually low. Effect of Food The presence of food or agents delaying gastric emptying can increase the bioavailability of nitrofurantoin. Distribution Nitrofurantoin is highly soluble in urine. Nitrofurantoin lacks the broader tissue distribution of other therapeutic agents approved for urinary tract infections. Elimination Excretion Nitrofurantoin is rapidly excreted in urine, to which it may impart a brown color. Following a dose regimen of 100 mg four times a day for 7 days, average urinary drug recoveries (0 hour to 24 hours) on Day 1 and Day 7 were 42.7% and 43.6% Nitrofurantoin is dialyzable. Specific Populations The pharmacokinetics of nitrofurantoin are unknown for the geriatric patients, pediatric patients, patients with hepatic impairment, or pregnant women. Differences between male and female patients, and racial or ethnic groups are unknown. Patients with Renal Impairment The reported urinary recoveries of nitrofurantoin after a single 100 mg oral dose and 100 mg four times a day in patients with varying renal function showed approximate linear relationship between the amount of nitrofurantoin recovered and creatinine clearance. Drug Interaction Studies Antacids such as magnesium trisilicate In a cross-over study, the in vivo absorption characteristics of nitrofurantoin and nitrofurantoin-magnesium trisilicate combination were evaluated in 6 healthy males. The administration of 5 g magnesium trisilicate with 100 mg nitrofurantoin reduced the rate and extent of nitrofurantoin excretion reflecting decrease in both rate and extent of its absorption [see Drug Interaction (7.1)]. Propantheline In a crossover study, the in vivo absorption characteristics of nitrofurantoin and propantheline (an anticholinergic agent) combination were evaluated in six subjects. Administration of 30 mg of propantheline 45 min prior to nitrofurantoin 100 mg administration resulted in a statistically significant increase in nitrofurantoin excretion, however, the clinical significance of this effect is unknown."],"adverse_reactions":["6 ADVERSE REACTIONS The following clinically significant adverse reactions are discussed in more detail in other sections of the labeling: Hypersensitivity Reactions [see Warnings and Precautions (5.1)] Pulmonary Reactions [see Warnings and Precautions (5.2)] Hepatotoxicity [see Warnings and Precautions (5.3)] Neuropathy [see Warnings and Precautions (5.4)] Hemolytic anemia [see Warnings and Precautions (5.5)] Clostridioides difficile -associated Diarrhea [see Warnings and Precautions (5.6)] Persistence or Reappearance of Bacteriuria [see Warnings and Precautions (5.7)] The following adverse reactions associated with the use of nitrofurantoin formulations, including nitrofurantoin oral suspension, were identified in clinical studies or post-marketing reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Respiratory : chronic, subacute, or acute pulmonary hypersensitivity reactions have occurred. Chronic pulmonary reactions have occurred generally in patients who have received continuous treatment for six months or longer. Malaise, dyspnea on exertion, cough, and altered pulmonary function are common manifestations which can occur insidiously. Radiologic and histologic findings of diffuse interstitial pneumonitis or fibrosis, or both, are also common manifestations of the chronic pulmonary reaction. Fever is prominent. The severity of chronic pulmonary reactions and their degrees of resolution appear to be related to the duration of therapy after the first clinical signs appear. Pulmonary function may be impaired permanently, even after cessation of therapy. The risk is greater when chronic pulmonary reactions are not recognized early. In subacute pulmonary reactions, fever and eosinophilia occur less often than in the acute form. Upon cessation of therapy, recovery may require several months. If the symptoms are not recognized as being drug-related and nitrofurantoin therapy is not stopped, the symptoms may become more severe. Acute pulmonary reactions are commonly manifested by fever, chills, cough, chest pain, dyspnea, pulmonary infiltration with consolidation of pleural effusion on x-ray, and eosinophilia. Acute reactions usually occur within the first week of treatment and are reversible with cessation of therapy. Resolution often is dramatic . Changes in EKG (e.g., non-specific ST/T wave changes, bundle branch block) have been reported in association with pulmonary reactions. Cyanosis has been reported. Hepatic : Hepatic reactions, including hepatitis, cholestatic jaundice, chronic active hepatitis, and hepatic necrosis, have occurred . Neurologic: Peripheral neuropathy, which may become severe or irreversible, has occurred. Fatalities have been reported. Conditions such as renal impairment (creatinine clearance under 60 mL per minute or clinically significant elevated serum creatinine), anemia, diabetes mellitus, electrolyte imbalance, vitamin B deficiency, and debilitating diseases may increase the possibility of peripheral neuropathy . Asthenia, vertigo, nystagmus, dizziness, headache, and drowsiness also have been reported with the use of nitrofurantoin. Benign intracranial hypertension (pseudotumor cerebri), confusion, depression, optic neuritis, and psychotic reactions have been reported. Bulging fontanels, as a sign of benign intracranial hypertension in infants, have been reported rarely. Dermatologic: Exfoliative dermatitis and erythema multiforme (including Stevens-Johnson syndrome) have been reported. Alopecia also has been reported. Allergic: A lupus-like syndrome associated with pulmonary reactions to nitrofurantoin has been reported. Also, angioedema; maculopapular, erythematous, or eczematous eruptions; pruritus; urticaria; anaphylaxis; arthralgia; myalgia; drug fever; and vasculitis (sometimes associated with pulmonary reactions) have been reported. Hypersensitivity reactions present the most frequent spontaneously-reported adverse reactions in worldwide post marketing experience with nitrofurantoin formulations, including nitrofurantoin oral suspension. Gastrointestinal: Nausea, emesis, and anorexia occur most often. Abdominal pain and diarrhea are less common gastrointestinal reactions. These dose-related reactions can be minimized by reduction of dosage. Sialadenitis and pancreatitis have been reported. There have been sporadic reports of pseudomembranous colitis with the use of nitrofurantoin. The onset of pseudomembranous colitis symptoms may occur during or after antibacterial treatment . Hematologic: Cyanosis secondary to methemoglobinemia has been reported. Miscellaneous: As with other antibacterial agents, superinfections caused by resistant organisms, e.g., Pseudomonas species or Candida species, can occur. There are sporadic reports of Clostridioides difficile superinfections, or pseudomembranous colitis, with the use of nitrofurantoin, including nitrofurantoin oral suspension. Laboratory Adverse Reactions The following laboratory adverse reactions have been reported with the use of nitrofurantoin formulations, including nitrofurantoin oral suspension; increased AST (SGOT), increased ALT (SGPT), decreased hemoglobin, increased serum phosphorus, eosinophilia, glucose-6-phosphate dehydrogenase deficiency anemia, agranulocytosis, leukopenia, granulocytopenia, hemolytic anemia, thrombocytopenia, megaloblastic anemia. In most cases, these hematologic abnormalities resolved following cessation of therapy. Aplastic anemia has been reported. The most common adverse reactions occurring in patients are nausea, vomiting, anorexia, vertigo, nystagmus, dizziness, headache, angioedema, rash, urticaria, pulmonary hypersensitivity reactions, hepatic reactions, peripheral neuropathy, increased aspartate aminotransferase, increased alanine aminotransferase, decreased hemoglobin, increased serum phosphorus, and eosinophilia (6) To report SUSPECTED ADVERSE REACTIONS, contact Northstar Rx LLC at 1-800-204-7821 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch ."],"contraindications":["4 CONTRAINDICATIONS Nitrofurantoin is contraindicated in: patients with known hypersensitivity to nitrofurantoin [see Warnings and Precautions (5.1)]. patients with a previous history of cholestatic jaundice/hepatic dysfunction associated with nitrofurantoin [see Warnings and Precautions (5.3)]. patients who have anuria, oliguria, or significant impairment of renal function (creatinine clearance under 60 mL per minute or clinically significant elevated serum creatinine) due to an increased risk of toxicity resulting from impaired excretion of the drug [see Warnings and Precautions (5.4)]. pregnant patients at term (38 weeks to 42 weeks gestation), during labor and delivery, or when the onset of labor is imminent and in pediatric patients younger than 1 month of age because of the possibility of hemolytic anemia due to immature erythrocyte enzyme systems (glutathione instability) [see Warnings and Precautions (5.5) and Use in Specific Populations (8.1 and 8.4)]. Known hypersensitivity to nitrofurantoin. (4) History of cholestatic jaundice/hepatic dysfunction associated with nitrofurantoin. (4) Patients who have anuria, oliguria, or significant impairment of renal function (creatinine clearance under 60 mL per minute or clinically significant elevated serum creatinine). (4) Pregnant patients at term (38 weeks to 42 weeks gestation), during labor and delivery, or when the onset of labor is imminent. (4) Pediatric Patients under one month of age. (4)"],"drug_interactions":["7 DRUG INTERACTIONS Antacids : Decreased absorption of nitrofurantoin. (7.1) Uricosuric drugs: Inhibit renal tubular secretion of nitrofurantoin. (7.2) 7.1 Antacids Antacids containing magnesium trisilicate, when administered concomitantly with nitrofurantoin, reduce both the rate and extent of absorption. The mechanism for this interaction probably is adsorption of nitrofurantoin onto the surface of magnesium trisilicate. If coadministration of nitrofurantoin with antacids containing magnesium trisilicate cannot be avoided, monitor for lack of efficacy [see Clinical Pharmacology (12.3)] . 7.2 Uricosuric Drugs Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin. The resulting increase in nitrofurantoin serum levels may increase toxicity, and the decreased urinary levels could lessen its efficacy as a urinary tract antibacterial. Therefore, monitor for nitrofurantoin adverse reactions when co-administering nitrofurantoin with uricosuric drugs. 7.3 Drug Interference with Laboratory Tests The presence of nitrofurantoin can cause a false-positive reaction for glucose in the urine when using Benedict's or Fehling's copper reduction reaction to determine the amount of reducing substances like glucose in the urine. Use glucose tests based on enzymatic glucose oxidase reactions to detect glucose in the urine."],"mechanism_of_action":["12.1 Mechanism of Action Nitrofurantoin is an antibacterial drug [ see Microbiology (12.4)] ."],"recent_major_changes":["Dosage and Administration (2) 1/2024"],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Nitrofurantoin is an antibacterial drug [ see Microbiology (12.4)] . 12.2 Pharmacodynamics Pharmacodynamic effects of nitrofurantoin are unknown. 12.3 Pharmacokinetics Absorption Orally administered nitrofurantoin is readily absorbed. Blood concentrations at therapeutic dosage are usually low. Effect of Food The presence of food or agents delaying gastric emptying can increase the bioavailability of nitrofurantoin. Distribution Nitrofurantoin is highly soluble in urine. Nitrofurantoin lacks the broader tissue distribution of other therapeutic agents approved for urinary tract infections. Elimination Excretion Nitrofurantoin is rapidly excreted in urine, to which it may impart a brown color. Following a dose regimen of 100 mg four times a day for 7 days, average urinary drug recoveries (0 hour to 24 hours) on Day 1 and Day 7 were 42.7% and 43.6% Nitrofurantoin is dialyzable. Specific Populations The pharmacokinetics of nitrofurantoin are unknown for the geriatric patients, pediatric patients, patients with hepatic impairment, or pregnant women. Differences between male and female patients, and racial or ethnic groups are unknown. Patients with Renal Impairment The reported urinary recoveries of nitrofurantoin after a single 100 mg oral dose and 100 mg four times a day in patients with varying renal function showed approximate linear relationship between the amount of nitrofurantoin recovered and creatinine clearance. Drug Interaction Studies Antacids such as magnesium trisilicate In a cross-over study, the in vivo absorption characteristics of nitrofurantoin and nitrofurantoin-magnesium trisilicate combination were evaluated in 6 healthy males. The administration of 5 g magnesium trisilicate with 100 mg nitrofurantoin reduced the rate and extent of nitrofurantoin excretion reflecting decrease in both rate and extent of its absorption [see Drug Interaction (7.1)]. Propantheline In a crossover study, the in vivo absorption characteristics of nitrofurantoin and propantheline (an anticholinergic agent) combination were evaluated in six subjects. Administration of 30 mg of propantheline 45 min prior to nitrofurantoin 100 mg administration resulted in a statistically significant increase in nitrofurantoin excretion, however, the clinical significance of this effect is unknown. 12.4 Microbiology Mechanism of Action Nitrofurantoin is reduced by a wide range of enzymes including bacterial flavoproteins to reactive intermediates which are damaging to macromolecules such as DNA and proteins. Resistance Nitrofurantoin is not active against most strains of Proteus species or Serratia species. It has no activity against Pseudomonas species. Although cross-resistance with other antibacterials may occur, cross resistance with sulfonamides has not been observed. Interaction with Other Antibacterials Antagonism has been demonstrated in vitro between nitrofurantoin and quinolones. Antibacterial Activity Nitrofurantoin has been shown to be active against most of the following bacteria both in vitro and in clinical infections: Aerobic bacteria Gram-positive bacteria Staphylococcus aureus Enterococcus species Gram-negative bacteria Escherichia coli Enterobacter species Klebsiella species The following in vitro data are available, but their clinical significance is unknown. Nitrofurantoin exhibits in vitro activity against the following bacteria; however, the safety and efficacy of nitrofurantoin in treating clinical infections due to these bacteria have not been established in adequate and well-controlled clinical trials. Aerobic bacteria Gram-positive bacteria Coagulase-negative staphylococci (including Staphylococcus epidermidis and Staphylococcus saprophyticus ) Streptococcus agalactiae Viridans group streptococci Gram-negative bacteria Citrobacter koseri Citrobacter freundii Klebsiella oxytoca Susceptibility Testing For specific information regarding susceptibility test interpretive criteria, and associated test methods and quality control standards recognized by FDA for this drug, please see: http://www.fda.gov/STIC ."],"indications_and_usage":["1 INDICATIONS & USAGE Nitrofurantoin is indicated in adults and pediatric patients 1 month of age and older for the treatment of urinary tract infections due to susceptible strains of Escherichia coli , Enterococcus species, Staphylococcus aureus , Klebsiella species and Enterobacter species. Limitations of Use Nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses [see Warnings and Precautions (5.7)]. Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of nitrofurantoin and other antibacterial drugs, nitrofurantoin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Nitrofurantoin is a nitrofuran antibacterial indicated in adults and pediatric patients 1 month of age and older for the treatment of urinary tract infections caused by susceptible bacteria. (1) Limitations of Use Nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses. (1) Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of nitrofurantoin and other antibacterial drugs, nitrofurantoin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. (1)"],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Hypersensitivity Reactions: Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving nitrofurantoin. If signs and symptoms of a hypersensitivity reaction occurs, immediately discontinue nitrofurantoin. (5.1) Pulmonary Reactions: Discontinue if sign and symptoms of pulmonary reactions occur and take appropriate measures. (5.2) Hepatotoxicity: Discontinue if signs/symptoms of hepatitis occur. Monitor liver function tests. (5.3) Neuropathy: Peripheral neuropathy has occurred. (5.4) Hemolytic Anemia: Discontinue if sign and symptoms of hemolysis occur. (5.5) Clostridioides difficile -associated diarrhea: Evaluate patients if diarrhea occurs. (5.6) 5.1 Hypersensitivity Reactions Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving nitrofurantoin [see Adverse Reactions (6)]. If signs and symptoms of a hypersensitivity reaction occurs, immediately discontinue nitrofurantoin and initiate appropriate medications and/or supportive care. Nitrofurantoin is contraindicated in patients with known hypersensitivity to nitrofurantoin. 5.2 Pulmonary Reactions Acute, subacute, or chronic pulmonary reactions have been reported in patients treated with nitrofurantoin. If these reactions occur, discontinue nitrofurantoin and take appropriate measures. Reports have cited pulmonary reactions as a contributing cause of death. Chronic pulmonary reactions (diffuse interstitial pneumonitis or pulmonary fibrosis, or both) can develop insidiously. These reactions occur generally in patients receiving therapy for six months or longer. Close monitoring of the pulmonary condition of patients receiving long-term therapy is warranted and requires that the benefits of therapy be weighed against potential risks [see Adverse Reactions (6)]. 5.3 Hepatotoxicity Hepatic reactions, including hepatitis, cholestatic jaundice, chronic active hepatitis, and hepatic necrosis, has occurred. Fatalities have been reported. The onset of chronic active hepatitis may be insidious. Monitor patients periodically for changes in biochemical tests that would indicate liver injury. If hepatitis occurs, discontinue nitrofurantoin immediately, and take appropriate measures. 5.4 Neuropathy Peripheral neuropathy, which may become severe or irreversible, has occurred. Fatalities have been reported. Conditions such as renal impairment (creatinine clearance under 60 mL per minute or clinically significant elevated serum creatinine), anemia, diabetes mellitus, electrolyte imbalance, vitamin B deficiency, and debilitating disease may enhance the occurrence of peripheral neuropathy. Monitor patients receiving long-term therapy periodically for changes in renal function. Optic neuritis has been reported with nitrofurantoin formulations [see Adverse Reactions (6)] . 5.5 Hemolytic Anemia Cases of hemolytic anemia of the primaquine-sensitivity type have been induced by nitrofurantoin. Hemolysis appears to be linked to a glucose-6-phosphate dehydrogenase deficiency in the red blood cells of the affected patients. This deficiency is found in 10 percent of Blacks and a small percentage of ethnic groups of Mediterranean and Near-Eastern origin. If hemolysis occurs, discontinue nitrofurantoin immediately; hemolysis ceases when the drug is withdrawn. 5.6 Clostridioides difficile-associated Diarrhea Clostridioides difficile -associated Diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including nitrofurantoin, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile . C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antibacterial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibacterial use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile , and institute surgical evaluation as clinically indicated. 5.7 Persistence or Reappearance of Bacteriuria Nitrofurantoin lacks the broader tissue distribution of other therapeutic agents approved for urinary tract infections. Consequently, many patients who are treated with nitrofurantoin are predisposed to persistence or reappearance of bacteriuria. If persistence or reappearance of bacteriuria occurs with symptoms of urinary tract infection, after treatment with nitrofurantoin, other therapeutic agents with broader tissue distribution should be selected. In considering the use of nitrofurantoin, lower eradication rates should be balanced against the increased potential for systemic toxicity and for the development of antibacterial resistance when agents with broader tissue distribution are utilized."],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis & Mutagenesis & Impairment Of Fertility Carcinogenesis Nitrofurantoin was not carcinogenic when fed to female Holtzman rats for 44.5 weeks or to female Sprague-Dawley rats for 75 weeks. Two chronic rodent bioassays utilizing male and female Sprague-Dawley rats and two chronic bioassays in Swiss mice and in BDF1 mice revealed no evidence of carcinogenicity. Nitrofurantoin presented evidence of carcinogenic activity in female B6C3F1 mice as shown by increased incidences of tubular adenomas, benign mixed tumors, and granulosa cell tumors of the ovary. In male F344/N rats, there were increased incidences of uncommon kidney tubular cell neoplasms, osteosarcomas of the bone, and neoplasms of the subcutaneous tissue. The significance of carcinogenicity findings relative to the therapeutic use of nitrofurantoin in humans is unknown. Mutagenesis Nitrofurantoin has been shown to induce point mutations in certain strains of Salmonella typhimurium and forward mutations in L5178Y mouse lymphoma cells. Nitrofurantoin induced increased numbers of sister chromatid exchanges and chromosomal aberrations in Chinese hamster ovary cells but not in human cells in culture. Results of the sex-linked recessive lethal assay in Drosophila were negative after administration of nitrofurantoin by feeding or by injection. Nitrofurantoin did not induce heritable mutation in the rodent models examined. The significance of mutagenicity findings relative to the therapeutic use of nitrofurantoin in humans is unknown. Impairment of Fertility The administration of high doses of nitrofurantoin to rats causes temporary spermatogenic arrest; this is reversible on discontinuing the drug."],"spl_unclassified_section":["17 PATIENT COUNSELING INFORMATION Administration Instructions Instruct the patients to: complete the full course of therapy; however, advise the patients or their caregiver to contact their physician if any unusual symptoms occur during therapy. take daily doses of nitrofurantoin with food, as food will further enhance tolerance and improve the absorption of the drug. shake nitrofurantoin oral suspension vigorously before use each time. use an oral dosing syringe to correctly measure the prescribed amount of nitrofurantoin oral suspension. Inform patients or caregivers that an appropriate size oral dosing syringe with graduations that align with the volume prescribed may be obtained from their pharmacy. Serious Allergic Reactions Advise patients that allergic reactions, including serious allergic reactions, could occur with nitrofurantoin and that serious reactions require immediate treatment. Advise patients to discontinue nitrofurantoin at the first sign of allergic reactions [see Warnings and Precautions (5.1)]. Diarrhea Advise patients that diarrhea is a common problem caused by antibacterial drugs, including nitrofurantoin which usually ends when the antibacterial drug is discontinued. Sometimes frequent watery and bloody diarrhea (with or without stomach cramps and fever) may occur even as late as two or more months after having taken the last dose of the antibacterial drug. If this occurs, advise patients to contact their physician as soon as possible [see Warnings and Precautions (5.6)]. Drug Interactions with Antacids Advise patients not to use antacid preparations containing magnesium trisilicate while taking nitrofurantoin [see Drug Interactions (7.1)]. Lactation Advise women not to breastfeed infants who are less than one month of age or who have G6PD deficiency during treatment with nitrofurantoin [see Use in Specific Populations (8.2)]. Antibacterial Resistance Patients should be counseled that antibacterial drugs including nitrofurantoin should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When nitrofurantoin is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of the therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by nitrofurantoin or other antibacterial drugs in the future. Change in Urine Color Inform patients that nitrofurantoin may impart a brown color to their urine [see Clinical Pharmacology (12.3)]. Manufactured for: Northstar Rx LLC Memphis, TN 38141 Toll-free: 1-800-206-7821 Manufactured by: Novitium Pharma LLC East Windsor, NJ 08520 Rev. 03/2024 LB4615-01"],"dosage_and_administration":["2 DOSAGE & ADMINISTRATION Adult Patients: 50 mg to 100 mg four times a day -the lower dosage level is recommended for uncomplicated urinary tract infections. (2.2) Pediatric Patients: 5 mg/kg to 7 mg/kg of body weight per 24 hours, given in four divided doses (contraindicated under one month of age). (2.3) 2.1 Recommended Dosage and Administration in Adult Patients The recommended dosage is 50 mg to 100 mg of nitrofurantoin four times a day. For long-term suppressive therapy in adults, a reduction of dosage to 50 mg to 100 mg at bedtime may be adequate . The benefits of long-term suppressive therapy should be balanced against the increased potential for systemic toxicity and for the development of antibacterial resistance [see Warnings and Precautions (5.2, 5.4, 5.6)]. Administer nitrofurantoin with food to improve drug absorption [see Clinical Pharmacology (12.3)] and, in some patients, tolerance. 2.2 Recommended Dosage and Administration in Pediatric Patients (1 month of age and older) The recommended dosage of nitrofurantoin is 5 mg/kg to 7 mg/kg of body weight per 24 hours, given in four divided doses in pediatric patients aged 1 month and older. Administer nitrofurantoin with food to improve drug absorption [ s ee Clinical Pharmacology (12.3)] and, in some patients, tolerance. Table 1 lists individual dosage volumes for nitrofurantoin oral suspension (25 mg/5 mL) based on body weight for pediatric patients. Table 1: Nitrofurantoin Oral Suspension Pediatric Dosing Table for Pediatric Patients 1 month of Age and Older Weight in Kilograms (kg) Pediatric Doses (mL), Frequency: Four times Daily 25 mg/5 mL oral suspension 4 kg or lower 1 Greater than 4 kg to 5 kg 1.4 Greater than 5 kg to 7 kg 1.8 Greater than 7 kg to 10 kg 2.5 Greater than 10 kg to 14 kg 3.5 Greater than 14 kg to 20 kg 5 Greater than 20 kg to 25 kg 7 Greater than 25 kg to 30 kg 8.5 Greater than 30 kg to 40 kg 10 40 kg or greater See Adult Dose To measure the correct pediatric doses, it is important to administer nitrofurantoin oral suspension with an appropriate size oral dosing syringe with graduations that align with the volume prescribed in Table 1 above. Continue therapy for one week or for at least 3 days after sterility of the urine is obtained. Continued infection indicates the need for reevaluation. For long-term suppressive therapy in pediatric patients, doses as low as 1 mg/kg per 24 hours, given in a single dose or in two divided doses, may be adequate [see Warnings and Precautions (5.2, 5.4, 5.6)]."],"spl_product_data_elements":["Nitrofurantoin Nitrofurantoin CITRIC ACID MONOHYDRATE GLYCERIN METHYLPARABEN PROPYLPARABEN WATER SODIUM CITRATE SUCRALOSE XANTHAN GUM DIMETHICONE NITROFURANTOIN NITROFURANTOIN Lemon Yellow"],"dosage_forms_and_strengths":["3 DOSAGE FORMS & STRENGTHS Nitrofurantoin Oral Suspension, USP is available as a lemon-yellow liquid with cherry flavor, free from extraneous particles for oral suspension containing 25 mg/5 mL of nitrofurantoin. Oral Suspension: 25 mg/5 mL. (3)"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS Lactation: Breastfeeding is not recommended in infants under one month of age or with glucose-6-phosphate dehydrogenase (G6PD) deficiency. (8.2) Pediatric Use: Nitrofurantoin is contraindicated in pediatric patients under one month of age. (8.4) 8.1 Pregnancy Risk Summary Nitrofurantoin is contraindicated in pregnant women at term (38 weeks to 42 weeks gestation), during labor and delivery, or when the onset of labor is imminent because of the possibility of hemolytic anemia in the infant (see Clinical Considerations). Published epidemiological studies, including cohort studies and case control studies, have reported inconsistent findings related to nitrofurantoin use during the first trimester and risk of major birth defects. These studies cannot definitively establish the presence or absence of risk due to several methodological limitations. The limited number of epidemiological studies available have not identified drug-associated risks of major birth defects, miscarriage or other adverse maternal or fetal outcomes. In animal reproduction studies, no fetotoxicity was observed when nitrofurantoin was administered orally to pregnant rats and rabbits, during organogenesis, at up to 6 times the recommended human dose (see Data ). The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Clinical Considerations Fetal/Neonatal Adverse Reactions Nitrofurantoin is not recommended in pregnant women at term (38 weeks to 42 weeks gestation), during labor and delivery, or when the onset of labor is imminent because of the possibility of hemolytic anemia due to immature erythrocyte enzyme systems (glutathione instability) [see Contraindications (4) and Warnings and Precautions (5.4)]. Data Animal Data Several reproduction studies have been performed in rabbits and rats at doses up to six times the human dose and have revealed no harm to the fetus due to nitrofurantoin. In a single published study conducted in mice at 68 times the human dose (based on mg/kg administered to the dam), growth retardation and a low incidence of minor and common malformations were observed. However, at 25 times the human dose, fetal malformations were not observed. Nitrofurantoin has been shown in one published transplacental carcinogenicity study to induce lung papillary adenomas in the F1 generation mice at doses 19 times the human dose on a mg/kg basis. The relationship of this finding to potential human carcinogenesis is presently unknown. 8.2 Lactation Risk Summary Nitrofurantoin is present in human breast milk following oral administration. There are insufficient data on the effect of nitrofurantoin on milk production. Infants less than one month of age or who have glucose-6-phosphate dehydrogenase (G6PD) deficiency are at risk for hemolytic anemia from nitrofurantoin exposure. Therefore, breastfeeding is not recommended in these infants. In a breastfed infant over the age of one month and with normal G6PD, the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for nitrofurantoin and any potential adverse effects on the breastfed infant from nitrofurantoin or from the underlying maternal condition. Monitor these infants for vomiting, diarrhea, and rash. 8.3 Females and Males of Reproductive Potential Infertility Male Based on findings from a fertility study conducted in 36 healthy male volunteers and an animal fertility study, nitrofurantoin may reversibly decrease spermatogenesis [see Nonclinical Toxicology (13.1)] . Nitrofurantoin doses of 10 mg/kg/day or greater in healthy human males may produce a slight to moderate spermatogenic arrest with a decrease in sperm count. The effect on fertility is unknown. 8.4 Pediatric Use Nitrofurantoin is contraindicated in pediatric patients younger than 1 month of age because of the possibility of hemolytic anemia due to immature erythrocyte enzyme systems (glutathione instability). [see Contraindications (4) and Warnings and Precautions (5.4)]. The safety and effectiveness of nitrofurantoin in pediatric patients aged 1 month of age and older for the treatment of urinary tract infections have been established."],"dosage_and_administration_table":["<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"570\"><colgroup><col width=\"35.3333333333333%\"/><col width=\"64.6666666666667%\"/></colgroup><tbody><tr styleCode=\"Botrule\"><td align=\"center\" rowspan=\"2\" styleCode=\"Lrule Rrule\" valign=\"middle\"><content styleCode=\"bold\">Weight in Kilograms (kg)</content></td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\"><content styleCode=\"bold\">Pediatric Doses (mL), Frequency: Four times Daily</content></td></tr><tr styleCode=\"Botrule\"><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"middle\"><content styleCode=\"bold\">25 mg/5 mL oral suspension</content></td></tr><tr styleCode=\"Botrule\"><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"middle\">4 kg or lower</td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">1</td></tr><tr styleCode=\"Botrule\"><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"middle\">Greater than 4 kg to 5 kg</td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">1.4</td></tr><tr styleCode=\"Botrule\"><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"middle\">Greater than 5 kg to 7 kg</td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">1.8</td></tr><tr styleCode=\"Botrule\"><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"middle\">Greater than 7 kg to 10 kg</td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">2.5</td></tr><tr styleCode=\"Botrule\"><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"middle\">Greater than 10 kg to 14 kg</td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">3.5</td></tr><tr styleCode=\"Botrule\"><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"middle\">Greater than 14 kg to 20 kg</td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">5</td></tr><tr styleCode=\"Botrule\"><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"middle\">Greater than 20 kg to 25 kg</td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">7</td></tr><tr styleCode=\"Botrule\"><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"middle\">Greater than 25 kg to 30 kg</td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">8.5</td></tr><tr styleCode=\"Botrule\"><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"middle\">Greater than 30 kg to 40 kg</td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">10</td></tr><tr><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"middle\">40 kg or greater</td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">See Adult Dose</td></tr></tbody></table>"],"package_label_principal_display_panel":["PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 72603-176-01 Nitrofurantoin Oral Suspension, USP 25 mg/ 5mL Urinary Tract Antibacterial 230 mL Rx Only Container Label Carton Label Container_Label Carton_Label"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis & Mutagenesis & Impairment Of Fertility Carcinogenesis Nitrofurantoin was not carcinogenic when fed to female Holtzman rats for 44.5 weeks or to female Sprague-Dawley rats for 75 weeks. Two chronic rodent bioassays utilizing male and female Sprague-Dawley rats and two chronic bioassays in Swiss mice and in BDF1 mice revealed no evidence of carcinogenicity. Nitrofurantoin presented evidence of carcinogenic activity in female B6C3F1 mice as shown by increased incidences of tubular adenomas, benign mixed tumors, and granulosa cell tumors of the ovary. In male F344/N rats, there were increased incidences of uncommon kidney tubular cell neoplasms, osteosarcomas of the bone, and neoplasms of the subcutaneous tissue. The significance of carcinogenicity findings relative to the therapeutic use of nitrofurantoin in humans is unknown. Mutagenesis Nitrofurantoin has been shown to induce point mutations in certain strains of Salmonella typhimurium and forward mutations in L5178Y mouse lymphoma cells. Nitrofurantoin induced increased numbers of sister chromatid exchanges and chromosomal aberrations in Chinese hamster ovary cells but not in human cells in culture. Results of the sex-linked recessive lethal assay in Drosophila were negative after administration of nitrofurantoin by feeding or by injection. Nitrofurantoin did not induce heritable mutation in the rodent models examined. The significance of mutagenicity findings relative to the therapeutic use of nitrofurantoin in humans is unknown. Impairment of Fertility The administration of high doses of nitrofurantoin to rats causes temporary spermatogenic arrest; this is reversible on discontinuing the drug."]},"tags":[{"label":"Nitrofuran Antibacterial","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"CDGSH iron-sulfur domain-containing protein 1","category":"target"},{"label":"CISD1","category":"gene"},{"label":"MPC2","category":"gene"},{"label":"G6PD","category":"gene"},{"label":"J01XE01","category":"atc"},{"label":"Oral","category":"route"},{"label":"Capsule","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Established","category":"status"},{"label":"Enterobacter Cystitis","category":"indication"},{"label":"Enterococcus Urinary Tract Infection","category":"indication"},{"label":"Escherichia coli urinary tract infection","category":"indication"},{"label":"Klebsiella cystitis","category":"indication"},{"label":"Staphylococcus Aureus Urinary Tract Infection","category":"indication"},{"label":"Staphylococcus Saprophyticus Urinary Tract Infection","category":"indication"},{"label":"Approved 1950s","category":"decade"},{"label":"Anti-Bacterial Agents","category":"pharmacology"},{"label":"Anti-Infective Agents","category":"pharmacology"},{"label":"Anti-Infective Agents, Urinary","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"URINARY TRACT INFECTION","source":"FDA FAERS","actionTaken":"2391 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"1952 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"1951 reports"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"1758 reports"},{"date":"","signal":"PAIN","source":"FDA FAERS","actionTaken":"1601 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"1503 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"1375 reports"},{"date":"","signal":"DIZZINESS","source":"FDA FAERS","actionTaken":"1261 reports"},{"date":"","signal":"DRUG HYPERSENSITIVITY","source":"FDA FAERS","actionTaken":"1243 reports"},{"date":"","signal":"VOMITING","source":"FDA FAERS","actionTaken":"1226 reports"}],"commonSideEffects":[{"effect":"Chronic pulmonary reactions","drugRate":"reported","severity":"serious"},{"effect":"Subacute pulmonary reactions","drugRate":"reported","severity":"serious"},{"effect":"Peripheral neuropathy","drugRate":"reported","severity":"serious"},{"effect":"Hepatic reactions","drugRate":"reported","severity":"serious"},{"effect":"Hepatitis","drugRate":"reported","severity":"serious"},{"effect":"Cholestatic jaundice","drugRate":"reported","severity":"serious"},{"effect":"Hepatic necrosis","drugRate":"reported","severity":"serious"},{"effect":"Pseudomembranous colitis","drugRate":"reported","severity":"serious"},{"effect":"Aplastic anemia","drugRate":"reported","severity":"serious"},{"effect":"Cyanosis","drugRate":"reported","severity":"mild"},{"effect":"Nausea","drugRate":"reported","severity":"mild"},{"effect":"Emesis","drugRate":"reported","severity":"mild"},{"effect":"Anorexia","drugRate":"reported","severity":"mild"},{"effect":"Abdominal pain","drugRate":"reported","severity":"mild"},{"effect":"Diarrhea","drugRate":"reported","severity":"mild"},{"effect":"Sialadenitis","drugRate":"reported","severity":"mild"},{"effect":"Pancreatitis","drugRate":"reported","severity":"mild"},{"effect":"Benign intracranial hypertension","drugRate":"reported","severity":"mild"},{"effect":"Confusion","drugRate":"reported","severity":"mild"},{"effect":"Depression","drugRate":"reported","severity":"mild"},{"effect":"Optic neuritis","drugRate":"reported","severity":"mild"},{"effect":"Psychotic reactions","drugRate":"reported","severity":"mild"},{"effect":"Exfoliative dermatitis","drugRate":"reported","severity":"mild"},{"effect":"Erythema multiforme","drugRate":"reported","severity":"mild"},{"effect":"Transient alopecia","drugRate":"reported","severity":"mild"}],"contraindications":["Acute hepatitis","Anemia due to enzyme deficiency","Anuria","Cholestatic hepatitis","Chronic hepatitis","Cobalamin deficiency","Deficiency of glucose-6-phosphate dehydrogenase","Diabetes mellitus","Drug-induced hepatitis","Fibrosis of lung","Impaired renal function disorder","Interstitial pneumonia","Obstructive hyperbilirubinemia","Oliguria","Optic neuritis","Peripheral nerve disease","Pseudomembranous enterocolitis","Vitamin B deficiency"],"specialPopulations":{"Pregnancy":"Pregnancy Category B. Several reproduction studies have been performed in rabbits and rats at doses up to six times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to nitrofurantoin. In single published study conducted in mice at 68 times the human dose (based on mg/kg administered to the dam), growth retardation and low incidence of minor and common malformations were observed. However, at 25 times the human dose, fetal","Geriatric use":"Clinical studies of nitrofurantoin capsules (macrocrystals) did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. Spontaneous reports suggest higher proportion of pulmonary reactions, including fatalities, in elderly patients; these differences appear to be related to the higher proportion of elderly patients with pulmonary disease.","Paediatric use":"Nitrofurantoin capsules (macrocrystals) are contraindicated in infants below the age of one month (see CONTRAINDICATIONS)."}},"trials":[],"aliases":[],"patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-09-18","unitCost":"$4.5628/ML","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$1,643","description":"NITROFURANTOIN 25 MG/5 ML SUSP","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=NITROFURANTOIN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:41:35.447357+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:41:43.094419+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:41:34.089213+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=NITROFURANTOIN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:41:43.907083+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:41:30.933951+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:41:30.934004+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:41:30.934015+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:41:45.414932+00:00"},"mechanism.oneSentence":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"12.1 Mechanism of Action Nitrofurantoin is an antibacterial drug [ see Microbiology (12.4)] .","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:41:50.241656+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: DNA inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:41:44.487427+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL572/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:41:44.390644+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA216385","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:41:30.934020+00:00"}},"allNames":"furadantin","offLabel":[],"synonyms":["nitrofurantoin sodium","nitrofurantoin","furadantin","furadantoin","nitrofurantoin, macrocrystalline","nitrofurantoin monohydrate"],"timeline":[{"date":"1953-02-06","type":"positive","source":"DrugCentral","milestone":"FDA approval"}],"approvals":[{"date":"1953-02-06","orphan":false,"company":"","regulator":"FDA"}],"brandName":"Furadantin","ecosystem":[{"indication":"Enterobacter Cystitis","otherDrugs":[{"name":"nitrofurazone","slug":"nitrofurazone","company":"Shire"},{"name":"norfloxacin","slug":"norfloxacin","company":""},{"name":"ofloxacin","slug":"ofloxacin","company":""}],"globalPrevalence":null},{"indication":"Enterococcus Urinary Tract Infection","otherDrugs":[{"name":"ampicillin","slug":"ampicillin","company":"Wyeth Ayerst"},{"name":"carbenicillin","slug":"carbenicillin","company":"Roerig"},{"name":"cefotaxime","slug":"cefotaxime","company":"Sanofi Aventis Us"},{"name":"cefradine","slug":"cefradine","company":"Apothecon"}],"globalPrevalence":null},{"indication":"Escherichia coli urinary tract infection","otherDrugs":[{"name":"amikacin","slug":"amikacin","company":"Apothecon"},{"name":"amoxicillin","slug":"amoxicillin","company":"Apothecon"},{"name":"aztreonam","slug":"aztreonam","company":"Bristol Myers Squibb"},{"name":"betaine","slug":"betaine","company":"Rare Dis Therap"}],"globalPrevalence":null},{"indication":"Klebsiella cystitis","otherDrugs":[{"name":"amoxicillin","slug":"amoxicillin","company":"Apothecon"},{"name":"aztreonam","slug":"aztreonam","company":"Bristol Myers Squibb"},{"name":"betaine","slug":"betaine","company":"Rare Dis Therap"},{"name":"cefadroxil","slug":"cefadroxil","company":""}],"globalPrevalence":null},{"indication":"Staphylococcus Aureus Urinary Tract Infection","otherDrugs":[{"name":"cefapirin","slug":"cefapirin","company":"Apothecon"},{"name":"cefotaxime","slug":"cefotaxime","company":"Sanofi Aventis Us"},{"name":"ceftizoxime","slug":"ceftizoxime","company":""},{"name":"clavulanic acid","slug":"clavulanic-acid","company":"Dr Reddys Labs Inc"}],"globalPrevalence":null},{"indication":"Staphylococcus Saprophyticus Urinary Tract Infection","otherDrugs":[{"name":"cefpodoxime proxetil","slug":"cefpodoxime-proxetil","company":""},{"name":"ciprofloxacin","slug":"ciprofloxacin","company":"Bayer Hlthcare"},{"name":"levofloxacin","slug":"levofloxacin","company":"Janssen Pharms"},{"name":"nitrofurazone","slug":"nitrofurazone","company":"Shire"}],"globalPrevalence":null}],"mechanism":{"target":"CDGSH iron-sulfur domain-containing protein 1","novelty":"Follow-on","targets":[{"gene":"CISD1","source":"DrugCentral","target":"CDGSH iron-sulfur domain-containing protein 1","protein":"CDGSH iron-sulfur domain-containing protein 1"},{"gene":"MPC2","source":"DrugCentral","target":"Mitochondrial pyruvate carrier 2","protein":"Mitochondrial pyruvate carrier 2"},{"gene":"G6PD","source":"DrugCentral","target":"Glucose-6-phosphate 1-dehydrogenase","protein":"Glucose-6-phosphate 1-dehydrogenase"}],"modality":"Small Molecule","drugClass":"Nitrofuran Antibacterial [EPC]","explanation":"Mechanism of Action. The mechanism of the antimicrobial action of nitrofurantoin is unusual among antibacterials.Nitrofurantoin is reduced by bacterial flavoproteins to reactive intermediates which inactivate or alter bacterial ribosomal proteins and other acromolecules. As result of such inactivations, the vital biochemical processes of protein synthesis, aerobic energy metabolism, DNA synthesis, RNA synthesis, and cell wall synthesis are inhibited. Nitrofurantoin is bactericidal in urine at therapeutic doses. The broad-based nature of this mode of action may explain the lack of acquired bacterial resistance to nitrofurantoin, as the necessary multiple and simultaneous mutations of the target macromolecules would likely be lethal to the bacteria.Interactions with Other AntibioticsAntagonism has been demonstrated in vitro between nitrofurantoin and quinolone antimicrobials. The clinical significance of this finding is unknown.Development of ResistanceDevelopment of resistance to nitrof","oneSentence":"Nitrofurantoin is an antibacterial drug.","technicalDetail":"Nitrofurantoin exerts its antibacterial effect by generating reactive intermediates that inactivate ribosomal proteins, damage DNA, and disrupt cellular processes, ultimately leading to bacterial cell death.","_target_confidence":0.5},"commercial":{"launchDate":"1953","_launchSource":"DrugCentral (FDA 1953-02-06, )"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1949","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=NITROFURANTOIN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=NITROFURANTOIN","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T14:41:14.189798","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T00:41:53.869492+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"aldesulfone","drugSlug":"aldesulfone","fdaApproval":"1974-05-24","relationship":"same-target"},{"drugName":"brexanolone","drugSlug":"brexanolone","fdaApproval":"2019-03-19","patentExpiry":"Nov 27, 2033","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"dapsone","drugSlug":"dapsone","fdaApproval":"1979-07-03","patentExpiry":"Nov 18, 2033","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"nitrofurazone","drugSlug":"nitrofurazone","fdaApproval":"1945-10-04","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"polydatin","drugSlug":"polydatin","fdaApproval":"","relationship":"same-target"},{"drugName":"prasterone","drugSlug":"prasterone","fdaApproval":"","patentExpiry":"Mar 19, 2031","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"primaquine","drugSlug":"primaquine","fdaApproval":"1952-01-23","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-target"}],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"nitrofurantoin","indications":{"approved":[{"name":"Enterobacter Cystitis","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"Adults and pediatric patients 1 month of age and older"},{"name":"Enterococcus Urinary Tract Infection","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"Adults and pediatric patients 1 month of age and older"},{"name":"Escherichia coli urinary tract infection","source":"DrugCentral","snomedId":301011002,"regulator":"FDA","eligibility":"Adults and pediatric patients 1 month of age and older"},{"name":"Klebsiella cystitis","source":"DrugCentral","snomedId":60867007,"regulator":"FDA","eligibility":"Adults and pediatric patients 1 month of age and older"},{"name":"Staphylococcus Aureus Urinary Tract Infection","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"Adults and pediatric patients 1 month of age and older"},{"name":"Staphylococcus Saprophyticus Urinary Tract Infection","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"Adults and pediatric patients 1 month of age and older"}],"offLabel":[{"name":"Prevention of Bacterial Urinary Tract Infection","source":"DrugCentral","drugName":"NITROFURANTOIN","evidenceCount":218,"evidenceLevel":"strong"}],"pipeline":[]},"currentOwner":"Casper Pharma Llc","drugCategory":"established","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"aldesulfone","brandName":"aldesulfone","genericName":"aldesulfone","approvalYear":"1974","relationship":"same-target"},{"drugId":"brexanolone","brandName":"brexanolone","genericName":"brexanolone","approvalYear":"2019","relationship":"same-target"},{"drugId":"dapsone","brandName":"dapsone","genericName":"dapsone","approvalYear":"1979","relationship":"same-target"},{"drugId":"nitrofurazone","brandName":"nitrofurazone","genericName":"nitrofurazone","approvalYear":"1945","relationship":"same-target"},{"drugId":"polydatin","brandName":"polydatin","genericName":"polydatin","approvalYear":"","relationship":"same-target"},{"drugId":"prasterone","brandName":"prasterone","genericName":"prasterone","approvalYear":"","relationship":"same-target"},{"drugId":"primaquine","brandName":"primaquine","genericName":"primaquine","approvalYear":"1952","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT05138822","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetic and Microbiological Investigation of GSK3882347 in Female Participants With Urinary Tract Infections","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-05-18","conditions":["Uncomplicated Urinary Tract Infections","Urinary Tract Infections"],"enrollment":140,"completionDate":"2024-12-03"},{"nctId":"NCT07202949","phase":"PHASE2","title":"A Clinical Trial of Extended (High) Treatment Dose Antibiotics in Combination With Methenamine Hippurate Compared to the Standard of Care (Either Prophylactic (Low) Dose Antibiotic Treatment or Methenamine Hippurate) in Females With Chronic Urinary Tract Infection","status":"NOT_YET_RECRUITING","sponsor":"University College, London","startDate":"2026-02-28","conditions":["Chronic Urinary Tract Infection"],"enrollment":192,"completionDate":"2027-11"},{"nctId":"NCT05274672","phase":"PHASE4","title":"Role of Prophylactic Postoperative Antibiotics in HoLEP","status":"WITHDRAWN","sponsor":"Baylor Research Institute","startDate":"2023-03-01","conditions":["Benign Prostatic Hyperplasia","Urinary Tract Infections"],"enrollment":0,"completionDate":"2025-02-20"},{"nctId":"NCT07369921","phase":"NA","title":"Pediatric Pilonidal Sinus Surgical Treatment","status":"RECRUITING","sponsor":"Zeliha Alicikus","startDate":"2026-01-30","conditions":["Surgery","Pilonidal Sinus","Pediatric"],"enrollment":80,"completionDate":"2026-05-30"},{"nctId":"NCT06723392","phase":"PHASE3","title":"Asymptomatic Bacteriuria in Pregnancy in Low- and Middle-IncomE Countries","status":"RECRUITING","sponsor":"NICHD Global Network for Women's and Children's Health","startDate":"2025-12-08","conditions":["Preterm Birth","Small for Gestational Age (SGA)","Stillbirth","Bacteriuria (Asymptomatic) in Pregnancy"],"enrollment":1134,"completionDate":"2028-11"},{"nctId":"NCT06332781","phase":"PHASE4","title":"Intravesical Gentamicin to Prevent Recurrent UTI","status":"RECRUITING","sponsor":"Women and Infants Hospital of Rhode Island","startDate":"2025-04-28","conditions":["Recurrent Uti"],"enrollment":30,"completionDate":"2026-05-31"},{"nctId":"NCT06907199","phase":"PHASE1","title":"Daily Nitrofurantoin Versus Bladder Fulguration Plus Daily Nitrofurantoin for Women With Recurrent Urinary Tract Infections","status":"NOT_YET_RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2026-01-31","conditions":["Recurrent UTIs","Cystitis Recurrent"],"enrollment":104,"completionDate":"2029-01-30"},{"nctId":"NCT05206500","phase":"PHASE4","title":"NextGen - Clinical Implication of Next Generation Sequencing","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2022-05-17","conditions":["Urinary Tract Infections"],"enrollment":100,"completionDate":"2028-12"},{"nctId":"NCT03522961","phase":"NA","title":"Cranberry Tablets Versus Nitrofurantoin Prophylaxis for Urinary Tract Infection Prevention After Urogynecologic Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2018-08-15","conditions":["Urinary Tract Infections","Pelvic Organ Prolapse","Urinary Incontinence"],"enrollment":142,"completionDate":"2026-12-31"},{"nctId":"NCT06190197","phase":"EARLY_PHASE1","title":"Prophylactic Antibiotics in Cystectomy With Diversion","status":"RECRUITING","sponsor":"University of Minnesota","startDate":"2024-05-13","conditions":["Muscle-Invasive Bladder Carcinoma","Radical Cystectomy","Ileal Conduit","Neobladder Diversion"],"enrollment":120,"completionDate":"2027-10-15"},{"nctId":"NCT06706362","phase":"PHASE4","title":"Assessing the Utility of Prophylactic Antibiotics at Time of Urethral Bulking Using Bulkamid (Bulkamid Study)","status":"RECRUITING","sponsor":"Ohio State University","startDate":"2025-09-15","conditions":["Stress Urinary Incontinence"],"enrollment":138,"completionDate":"2027-10-15"},{"nctId":"NCT07209150","phase":"PHASE3","title":"Randomized Controlled Trial of Different Antibiotic Duration Prior to Prostate Enucleation Surgery","status":"NOT_YET_RECRUITING","sponsor":"Ohio State University","startDate":"2026-01-01","conditions":["BPH With Urinary Obstruction","Antibiotic Prophylaxis"],"enrollment":250,"completionDate":"2028-07-15"},{"nctId":"NCT07202832","phase":"NA","title":"Urine Alkalinization for UTI in Women: RCT","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2025-10-15","conditions":["UTI - Urinary Tract Infection"],"enrollment":50,"completionDate":"2027-01-01"},{"nctId":"NCT07198919","phase":"PHASE1,PHASE2","title":"Comparison of Inter-appointment Pain Reduction During Root Canal Treatment in Symptomatic Apical Periodontitis by Using Intracanal Medicaments; Chlorhexidine Gel and Single Antibiotic Paste Nitrofurantoin","status":"ENROLLING_BY_INVITATION","sponsor":"Altamash Institute of Dental Medicine","startDate":"2025-05-20","conditions":["Intracanal Medicament"],"enrollment":220,"completionDate":"2025-11-30"},{"nctId":"NCT07186465","phase":"PHASE4","title":"Microbiome-Modulating Prophylaxis RCT: Antibiotic vs Gynoflor in Postmenopausal Women With Recurrent Cystitis","status":"RECRUITING","sponsor":"Mahidol University","startDate":"2025-09-11","conditions":["Cystitis, Recurrent","Urinary Tract Infections"],"enrollment":100,"completionDate":"2026-08-30"},{"nctId":"NCT07025044","phase":"","title":"Assessing the Genitourinary Microbiome of Women With Overactive Bladder Undergoing Onabotulinum Toxin Type A Intradetrusor Injections","status":"RECRUITING","sponsor":"Alexis Dieter","startDate":"2025-09-03","conditions":["Overactive Bladder (OAB)","Urge Incontinence"],"enrollment":40,"completionDate":"2026-06-01"},{"nctId":"NCT04959331","phase":"PHASE4","title":"Clinical Effectiveness and Bacteriological Eradication of 4 Short-course Antibiotics for Uncomplicated UTIs in Women.","status":"COMPLETED","sponsor":"Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina","startDate":"2021-11-02","conditions":["Urinary Tract Infections"],"enrollment":1000,"completionDate":"2024-12-31"},{"nctId":"NCT05726318","phase":"PHASE4","title":"Randomized Trial of Culture Directed Versus Empiric Antibiotics for Urinary Tract Infections in Older Women","status":"COMPLETED","sponsor":"Megan Bradley","startDate":"2023-02-17","conditions":["UTI"],"enrollment":70,"completionDate":"2024-08-02"},{"nctId":"NCT04502095","phase":"PHASE4","title":"Prophylactic Antibiotics for Urinary Tract Infections After Robot-Assisted Radical Cystectomy","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2020-09-02","conditions":["Bladder Carcinoma","Refractory Bladder Carcinoma","Urinary Tract Infection"],"enrollment":89,"completionDate":"2025-03-13"},{"nctId":"NCT06953271","phase":"PHASE4","title":"Methenamine Hippurate Following Intradetrusor OnabotulinumtoxinA Injection","status":"NOT_YET_RECRUITING","sponsor":"Women and Infants Hospital of Rhode Island","startDate":"2025-05-15","conditions":["Overactive Bladder (OAB)","Urinary Tract Infection (Diagnosis)"],"enrollment":164,"completionDate":"2027-01-01"},{"nctId":"NCT05630833","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety With Gepotidacin in Japanese Female Participants With Uncomplicated Urinary Tract Infection (Acute Cystitis)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2023-01-11","conditions":["Urinary Tract Infections"],"enrollment":380,"completionDate":"2024-02-02"},{"nctId":"NCT02829060","phase":"NA","title":"Endourology Disease Group Excellence (EDGE) Consortium: Antibiotics (Abx) for Percutaneous Nephrolithotomy (PCNL) Part 2","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2016-01","conditions":["Nephrolithiasis","Urinary Tract Infection (UTI)","Sepsis"],"enrollment":330,"completionDate":"2025-03"},{"nctId":"NCT06387329","phase":"PHASE4","title":"Bladder Botox UTI Antibiotic Prophylaxis","status":"RECRUITING","sponsor":"Walter Reed National Military Medical Center","startDate":"2024-04-04","conditions":["Overactive Bladder","Bladder Pain Syndrome"],"enrollment":100,"completionDate":"2025-06-30"},{"nctId":"NCT06815549","phase":"PHASE3","title":"An Open Clinical Trial of the Safety and Efficacy of the Drug Fluorothiazinone, 300 Mg Tablets with the Participation of Adult Patients with Chronic Bacterial Cystitis\"","status":"NOT_YET_RECRUITING","sponsor":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","startDate":"2025-02-17","conditions":["P. Aeruginosa","Baumannii","Klebsiella Pneumonia","E.coli Infections","Enterococcus Faecalis Infection","Chronic Bacterial Cystitis"],"enrollment":280,"completionDate":"2025-12-31"},{"nctId":"NCT05553743","phase":"","title":"Researchers At UC San Diego Are Learning About the Benefits of Human Milk and How It Influences Infant and Child Health","status":"RECRUITING","sponsor":"University of California, San Diego","startDate":"2014-03-27","conditions":["Breastfeeding","COVID-19 Infection","COVID-19 Vaccine","Remdesivir","Antibiotics"],"enrollment":5000,"completionDate":"2040-03"},{"nctId":"NCT06709196","phase":"PHASE4","title":"Clinical Trial Testing Whether Targeted Antibiotic Prophylaxis Can Reduce Infections After Cystectomy Compared to Empiric Prophylaxis","status":"RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2025-01-07","conditions":["Cystectomy","Bladder Cancer Requiring Cystectomy","Postoperative Infections","Antibiotic Prophylaxis","Ileal Conduit"],"enrollment":248,"completionDate":"2027-01"},{"nctId":"NCT05652374","phase":"PHASE4","title":"Gag Therapy for Recurrent Urinary Tract Infection Assessing Comparability to International Nitrofurantoin Gold Standard Study","status":"RECRUITING","sponsor":"Radboud University Medical Center","startDate":"2022-10-20","conditions":["Recurrent Urinary Tract Infection"],"enrollment":100,"completionDate":"2027-10"},{"nctId":"NCT06518291","phase":"PHASE4","title":"COMPARISON OF NITROFURANTOIN WITH FOSFOMYCIN in TREATING CYSTITIS IN WOMEN","status":"NOT_YET_RECRUITING","sponsor":"Shalamar Institute of Health Sciences","startDate":"2025-01","conditions":["Urinary Tract Infections"],"enrollment":392,"completionDate":"2025-06"},{"nctId":"NCT00649285","phase":"PHASE1","title":"Food Study of Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg and Macrobid® Capsules 100 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2002-10","conditions":["Healthy"],"enrollment":71,"completionDate":"2002-11"},{"nctId":"NCT00649506","phase":"PHASE1","title":"Food Study of Nitrofurantoin Macrocrystals 100 mg Capsules and Macrodantin® 100 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2003-09","conditions":["Healthy"],"enrollment":28,"completionDate":"2003-09"},{"nctId":"NCT01018342","phase":"PHASE1","title":"Fed Study of Mylan Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg and Macrobid® Capsules 100 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2002-07","conditions":["Healthy"],"enrollment":80,"completionDate":""},{"nctId":"NCT05519072","phase":"PHASE4","title":"Use of Prophylactic Antibiotics Prior to OnabotulinumtoxinA","status":"RECRUITING","sponsor":"Atlantic Health System","startDate":"2022-08-16","conditions":["Antibiotic Prophylaxis"],"enrollment":140,"completionDate":"2024-08-16"},{"nctId":"NCT04496726","phase":"PHASE2","title":"Cranberry and Quillaja on Symptoms of Uncomplicated UTI","status":"TERMINATED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2021-01-01","conditions":["Urinary Tract Infections","UTI","UTI - Lower Urinary Tract Infection"],"enrollment":2,"completionDate":"2023-06-01"},{"nctId":"NCT05719285","phase":"PHASE4","title":"Prophylactic Antibiotic Administration for Bladder OnabotulinumtoxinA Injection","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2022-12-06","conditions":["Overactive Bladder","Overactive Bladder Syndrome","Urge Incontinence","Urinary Incontinence, Urge"],"enrollment":100,"completionDate":"2023-06-08"},{"nctId":"NCT03508921","phase":"PHASE4","title":"Comparison of Methods for Prevention of Urinary Tract Infection Following Botox Injection","status":"TERMINATED","sponsor":"Vanderbilt University Medical Center","startDate":"2018-07-01","conditions":["Overactive Bladder","Urinary Tract Infections"],"enrollment":22,"completionDate":"2022-06-01"},{"nctId":"NCT02021006","phase":"PHASE3","title":"Antibiotic Prophylaxis and Renal Damage In Congenital Abnormalities of the Kidney and Urinary Tract","status":"UNKNOWN","sponsor":"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","startDate":"2013-12","conditions":["Vesicoureteral Reflux","Renal Hypodysplasia, Nonsyndromic, 1","Chronic Kidney Disease"],"enrollment":292,"completionDate":"2025-01"},{"nctId":"NCT04187144","phase":"PHASE3","title":"Comparative Study to Evaluate Efficacy and Safety of Gepotidacin to Nitrofurantoin in Treatment of Uncomplicated Urinary Tract Infection (UTI)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2020-04-23","conditions":["Urinary Tract Infections"],"enrollment":1606,"completionDate":"2022-12-01"},{"nctId":"NCT01572532","phase":"NA","title":"Maternal Genitourinary Infections and Adverse Perinatal Outcomes","status":"COMPLETED","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2010-08","conditions":["Maternal Infection Affecting Newborn"],"enrollment":9712,"completionDate":"2016-03-17"},{"nctId":"NCT04020341","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Gepotidacin in the Treatment of Uncomplicated Urinary Tract Infection (UTI)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-10-17","conditions":["Urinary Tract Infections"],"enrollment":1531,"completionDate":"2022-11-30"},{"nctId":"NCT05702762","phase":"PHASE2","title":"Single Dose Aminoglycosides for Acute Uncomplicated Cystitis in the Emergency Department Setting","status":"UNKNOWN","sponsor":"Mercy Health Ohio","startDate":"2022-10-01","conditions":["Urinary Tract Infections"],"enrollment":160,"completionDate":"2024-06-30"},{"nctId":"NCT03877289","phase":"PHASE4","title":"Efficacy of Oxybutynin in Paediatric Cystitis","status":"COMPLETED","sponsor":"University of Calgary","startDate":"2008-10","conditions":["Cystitis"],"enrollment":81,"completionDate":"2014-07"},{"nctId":"NCT05384197","phase":"PHASE3","title":"Enhanced Versus Extended Preoperative Antibiotic Prophylaxis Regimens for Retrograde Intrarenal Surgery in High Infectious Risk Patients","status":"UNKNOWN","sponsor":"Mansoura University","startDate":"2022-05-01","conditions":["Renal Stone"],"enrollment":280,"completionDate":"2023-07-01"},{"nctId":"NCT05600023","phase":"PHASE4","title":"The Effectiveness of Single Antibiotic Paste Nitrofurantoin Versus Double Antibiotic Paste","status":"COMPLETED","sponsor":"Altamash Institute of Dental Medicine","startDate":"2022-08-01","conditions":["Pain","Symptomatic Irreversible Pulpitis"],"enrollment":60,"completionDate":"2022-10-24"},{"nctId":"NCT03287089","phase":"PHASE4","title":"Nitrofurantoin Administration for the Prevention of Short-Term Catheter Associated Urinary Tract Infection After Pelvic Surgery","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2017-09-29","conditions":["Catheter-Associated Urinary Tract Infection"],"enrollment":164,"completionDate":"2019-06-01"},{"nctId":"NCT02375295","phase":"PHASE4","title":"Struvite Stones Antibiotic Study","status":"UNKNOWN","sponsor":"University of British Columbia","startDate":"2015-03","conditions":["Kidney Stones"],"enrollment":28,"completionDate":"2023-12"},{"nctId":"NCT05254808","phase":"PHASE3","title":"EXtended Use of FOsfomycin for the Treatment of CYstitis in Primary Care","status":"TERMINATED","sponsor":"MJM Bonten","startDate":"2021-09-06","conditions":["Urinary Tract Infections"],"enrollment":13,"completionDate":"2022-02-14"},{"nctId":"NCT05074628","phase":"EARLY_PHASE1","title":"Effect of Nitrofurantion Used as an Intracanal Medicament","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2021-12-01","conditions":["Intracanal Medication"],"enrollment":38,"completionDate":"2023-12-01"},{"nctId":"NCT02357758","phase":"PHASE4","title":"Effects of Antibiotic Prophylaxis on Recurrent UTI in Children","status":"COMPLETED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2012-09","conditions":["Urinary Tract Infection","Recurrent Urinary Tract Infection"],"enrollment":59,"completionDate":"2016-03"},{"nctId":"NCT04900571","phase":"PHASE4","title":"Comparison of Nitrofurantoin and Calcium Hydroxide as Intracanal Medicaments in Alleviating Post-operative Pain","status":"COMPLETED","sponsor":"Altamash Institute of Dental Medicine","startDate":"2021-01-01","conditions":["Pain, Postoperative","Irreversible Pulpitis"],"enrollment":60,"completionDate":"2021-05-18"},{"nctId":"NCT02512198","phase":"NA","title":"Electronic Prescription Data to Improve Primary Care Prescribing","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2015-07","conditions":["Physician's Practice Patterns"],"enrollment":236,"completionDate":"2017-07-01"},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":["Osteomyelitis"],"enrollment":11,"completionDate":"2018-11-07"},{"nctId":"NCT04285320","phase":"PHASE4","title":"Antibiotic Bladder Instillations vs. Oral Suppression for the Treatment of Recurrent Urinary Tract Infections","status":"UNKNOWN","sponsor":"Atlantic Health System","startDate":"2021-03","conditions":["Recurrent Urinary Tract Infection"],"enrollment":100,"completionDate":"2023-04"},{"nctId":"NCT03716804","phase":"PHASE4","title":"Establish the Relationship Between Shift in Prescribing Pattern and Associated Shift in Sensitivity Pattern of Causative Microbes in UTI Patients in a Closed Community","status":"COMPLETED","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2018-06-06","conditions":["Uncomplicated Urinary Tract Infection","Antibiotic Resistant Infection"],"enrollment":62,"completionDate":"2019-01-31"},{"nctId":"NCT03425396","phase":"PHASE2","title":"Oral Omadacycline vs. Oral Nitrofurantoin for the Treatment of Cystitis","status":"COMPLETED","sponsor":"Paratek Pharmaceuticals Inc","startDate":"2018-01-04","conditions":["Uncomplicated Urinary Tract Infection","Cystitis"],"enrollment":225,"completionDate":"2019-06-05"},{"nctId":"NCT01507974","phase":"NA","title":"Examination of the Efficacy of Preventive Antibiotic Treatment During the Puerperium Among Pregnant Women With Recurrent Urinary Tract Infections","status":"COMPLETED","sponsor":"HaEmek Medical Center, Israel","startDate":"2012-01-16","conditions":["Pregnancy Complications"],"enrollment":220,"completionDate":"2015-01-01"},{"nctId":"NCT03275623","phase":"PHASE4","title":"Management of Sub-Clinical Bacteriuria in Pregnancy","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2017-09-15","conditions":["Cystitis","Cystitis;Puerperium","Pyelonephritis"],"enrollment":60,"completionDate":"2019-03-18"},{"nctId":"NCT02789579","phase":"EARLY_PHASE1","title":"The Preventive Infection Role of One Week Antibiotics Before Minimally Invasive Upper Tract Lithotomy","status":"UNKNOWN","sponsor":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2016-09","conditions":["Complication of Surgical Procedure"],"enrollment":150,"completionDate":"2019-12"},{"nctId":"NCT02384200","phase":"PHASE4","title":"A Randomized Trial of Preoperative Prophylactic Antibiotics Prior to Kidney Stone Surgery (Percutaneous Nephrolithotomy [PCNL])","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2015-03","conditions":["Nephrolithiasis","Urinary Tract Infections"],"enrollment":86,"completionDate":"2019-06-01"},{"nctId":"NCT03362697","phase":"NA","title":"Lactobacillus Reuteri for Treatment of Uncomplicated UTI in Pregnant Women","status":"COMPLETED","sponsor":"Innovacion y Desarrollo de Estrategias en Salud","startDate":"2017-12-15","conditions":["Urinary Tract Infection in Pregnancy"],"enrollment":150,"completionDate":"2019-06-18"},{"nctId":"NCT03299387","phase":"PHASE4","title":"INtravesical Antimicrobial Agents v STANDard Oral Antibiotics for the Treatment of Acute UTI in Women With rUTI","status":"WITHDRAWN","sponsor":"Mayo Clinic","startDate":"2017-06-28","conditions":["Urinary Tract Infections"],"enrollment":0,"completionDate":"2018-07-05"},{"nctId":"NCT02727322","phase":"PHASE4","title":"Nitrofurantoin Prophylaxis During Catheter-managed Acute Urinary Retention After Pelvic Reconstructive Surgery","status":"COMPLETED","sponsor":"Halina M Zyczynski, MD","startDate":"2016-08","conditions":["Pelvic Organ Prolapse"],"enrollment":154,"completionDate":"2018-05-12"},{"nctId":"NCT01886001","phase":"NA","title":"Topical Umbilical Cord Care for the Prevention of Colonization and Invasive Infections","status":"COMPLETED","sponsor":"University of Virginia","startDate":"2012-11","conditions":["Colonization"],"enrollment":53,"completionDate":"2013-07"},{"nctId":"NCT02911662","phase":"NA","title":"Treatment of Asymptomatic Bacteriuria in Pregnancy","status":"TERMINATED","sponsor":"Trinity Health Michigan","startDate":"2016-09","conditions":["Bacteriuria (Asymptomatic) in Pregnancy"],"enrollment":13,"completionDate":"2018-01"},{"nctId":"NCT02145338","phase":"PHASE4","title":"Antibiotic Prophylaxis for Clean Intermittent Catheterisation","status":"COMPLETED","sponsor":"Newcastle-upon-Tyne Hospitals NHS Trust","startDate":"2013-09","conditions":["Urinary Tract Infections, Recurrent"],"enrollment":404,"completionDate":"2017-02-22"},{"nctId":"NCT03275519","phase":"NA","title":"Antibiotic Use in Distal Hypospadias Repair","status":"COMPLETED","sponsor":"Arkansas Children's Hospital Research Institute","startDate":"2015-01-19","conditions":["Hypospadias"],"enrollment":48,"completionDate":"2017-04-19"},{"nctId":"NCT01749605","phase":"PHASE4","title":"A Pilot Comparison of Short-course Nitrofurantoin in Females With Uncomplicated Bacterial Cystitis in the Emergency Department","status":"COMPLETED","sponsor":"University of Iowa","startDate":"2010-10","conditions":["Uncomplicated Bacterial Cystitis"],"enrollment":35,"completionDate":"2012-01"},{"nctId":"NCT01966653","phase":"PHASE4","title":"Study Comparing Nitrofurantoin to Fosfomycin for Acute Urinary Tract Infection in Women","status":"UNKNOWN","sponsor":"University Hospital, Geneva","startDate":"2013-10","conditions":["Urinary Tract Infections","Cystitis"],"enrollment":600,"completionDate":"2017-08"},{"nctId":"NCT03106103","phase":"","title":"Incidence of Symptomatic and Asymptomatic Bacteriuria After Urodynamic Study in Women","status":"COMPLETED","sponsor":"Federal University of São Paulo","startDate":"2009-02","conditions":["Female Stress Incontinence"],"enrollment":217,"completionDate":"2014-12"},{"nctId":"NCT01450800","phase":"PHASE4","title":"Suppressive Therapy With Oral Antibiotics for Prevention of Postoperative Urinary Tract Infection (UTI)","status":"COMPLETED","sponsor":"Duke University","startDate":"2011-08","conditions":["Urinary Tract Infection"],"enrollment":163,"completionDate":"2013-09"},{"nctId":"NCT00141037","phase":"PHASE1,PHASE2","title":"Steroid-Free Versus Steroid-Based Immunosuppression in Pediatric Renal (Kidney) Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2004-03","conditions":["Kidney Diseases","Kidney Transplantation","Kidney Transplant","Renal Transplantation","Renal Transplant"],"enrollment":130,"completionDate":"2010-11"},{"nctId":"NCT00734968","phase":"PHASE4","title":"Does Treatment With Macrobid Reduce Urinary Tract Infections in Patients Receiving a Sub-Urethral Sling for Incontinence","status":"COMPLETED","sponsor":"University of Missouri-Columbia","startDate":"2008-05","conditions":["Stress Incontinence"],"enrollment":161,"completionDate":"2010-05"},{"nctId":"NCT00678041","phase":"NA","title":"Nitrofurantoin and Urinary Tract Infections (UTIs)","status":"TERMINATED","sponsor":"University of Pittsburgh","startDate":"2008-05","conditions":["Urinary Tract Infections"],"enrollment":10,"completionDate":"2009-05"},{"nctId":"NCT02323087","phase":"NA","title":"Point of Care Susceptibility Testing in Primary Care","status":"COMPLETED","sponsor":"University of Copenhagen","startDate":"2015-03","conditions":["Urinary Tract Infections"],"enrollment":377,"completionDate":"2016-05"},{"nctId":"NCT00382343","phase":"PHASE4","title":"A Randomized Controlled Trial on Antibiotic Prophylaxis in Children With Vesico-Ureteral Reflux","status":"COMPLETED","sponsor":"IRCCS Burlo Garofolo","startDate":"1999-11","conditions":["Pyelonephritis","Renal Scars"],"enrollment":96,"completionDate":"2007-03"},{"nctId":"NCT00752375","phase":"PHASE3","title":"Antibiotic Prophylaxis in Children With Pyelonephritis","status":"WITHDRAWN","sponsor":"University of Alberta","startDate":"2009-02","conditions":["Pyelonephritis"],"enrollment":0,"completionDate":"2014-12"},{"nctId":"NCT01584765","phase":"","title":"Rechallenge, Potential Drug Induced Liver Injury (Kaiser)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-02","conditions":["Drug-induced Liver Injury"],"enrollment":1,"completionDate":"2013-04"},{"nctId":"NCT00391651","phase":"PHASE2","title":"Short Course Nitrofurantoin for Acute Cystitis","status":"COMPLETED","sponsor":"University of Washington","startDate":"2002-01","conditions":["Urinary Tract Infection"],"enrollment":338,"completionDate":"2005-07"},{"nctId":"NCT02092558","phase":"","title":"Evaluation of Immunological Disorders of T Lymphocytes and Endocrinological Disorders as Pathogen Factors in Patients With Metaplasia of Urinary Bladder","status":"COMPLETED","sponsor":"Children's Hospital, Dziekanów Leśny, Poland","startDate":"2005-01","conditions":["The Follow-up Duration Was 1-8 Years.","The Main Reasons Behind Visiting the Hospital Were Recurrent Urinary Tract Infection,","Urinary Urgencies, Pollakiuria, Difficulty in Initiating Micturition, Pain in Hypogastrium,","Night Wetting and Day Wetting, Menstruation's Disorders, Urolithiasis, Defects of Urinary","System and Hematuria."],"enrollment":2,"completionDate":"2013-12"},{"nctId":"NCT01893060","phase":"NA","title":"Umbilical Cord Care for the Prevention of Colonization","status":"UNKNOWN","sponsor":"University of Virginia","startDate":"2013-07","conditions":["Line Insertion Site","Central Line-associated Bloodstream Infection (CLABSI)"],"enrollment":100,"completionDate":"2014-07"},{"nctId":"NCT00826670","phase":"PHASE4","title":"Enterobacteriaceae Producing Extended-spectrum β-lactamases (ESBL) Decolonization Study","status":"COMPLETED","sponsor":"University Hospital, Geneva","startDate":"2009-06","conditions":["Enterobacteriaceae Infections"],"enrollment":58,"completionDate":"2012-08"},{"nctId":"NCT01349738","phase":"","title":"Asymptomatic Bacteriuria & Risk of Urinary Tract Infection in Renal Transplants","status":"UNKNOWN","sponsor":"Rice, James C., M.D.","startDate":"2011-05","conditions":["Bacteriuria","Urinary Tract Infections","Asymptomatic Infections","Transplantation Infection"],"enrollment":200,"completionDate":"2013-05"},{"nctId":"NCT01092351","phase":"PHASE4","title":"Efficacy and Safety of Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infections in Adults","status":"COMPLETED","sponsor":"Mepha Ltd.","startDate":"2007-01","conditions":["Urinary Tract Infection"],"enrollment":37,"completionDate":"2008-09"},{"nctId":"NCT00778583","phase":"NA","title":"Bioequivalence Study of Nitrofurantoin 100 mg Capsules Under Fed Conditions","status":"COMPLETED","sponsor":"Ranbaxy Laboratories Limited","startDate":"2003-09","conditions":["Healthy"],"enrollment":40,"completionDate":"2003-12"},{"nctId":"NCT00361998","phase":"PHASE4","title":"Nitrofurantoin Macrocrystals 3 Days Versus 7 Days in the Treatment of Women With Uncomplicated Cystitis","status":"WITHDRAWN","sponsor":"HaEmek Medical Center, Israel","startDate":"2006-09","conditions":["Cystitis"],"enrollment":400,"completionDate":"2007-01"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Capsule","formulations":[{"form":"CAPSULE","route":"ORAL","productName":"NITROFURANTION"},{"form":"CAPSULE","route":"ORAL","productName":"NITROFURANTOIN"},{"form":"CAPSULE","route":"ORAL","productName":"NITROFURANTOIN (monohydrate/macrocrystals)"},{"form":"CAPSULE","route":"ORAL","productName":"NITROFURANTOIN MACROCRYSTALS"},{"form":"CAPSULE","route":"ORAL","productName":"Nitrofurantion"},{"form":"CAPSULE","route":"ORAL","productName":"Nitrofurantoin"},{"form":"CAPSULE","route":"ORAL","productName":"Nitrofurantoin\n(monohydrate/macrocrystals)"},{"form":"CAPSULE","route":"ORAL","productName":"Nitrofurantoin \n(monohydrate/macrocrystals)"},{"form":"CAPSULE","route":"ORAL","productName":"Nitrofurantoin (monohydrate/macrocrystals)"},{"form":"CAPSULE","route":"ORAL","productName":"Nitrofurantoin Macrocrystals"},{"form":"CAPSULE","route":"ORAL","productName":"Nitrofurantoin Monohydrate/Macrocrystal"},{"form":"CAPSULE","route":"ORAL","productName":"Nitrofurantoin Monohydrate/Macrocrystals"},{"form":"CAPSULE","route":"ORAL","productName":"Nitrofurantoin macrocrystals"},{"form":"CAPSULE","route":"ORAL","productName":"Nitrofurantoin monohydrate/macrocrystals(monohydrate/macrocrystals)"},{"form":"CAPSULE","route":"ORAL","productName":"Nitrofurantoin(monohydrate/macrocrystals)"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000147151","MMSL":"181427","NDDF":"002852","UNII":"927AH8112L","VUID":"4018849","CHEBI":"CHEBI:71415","VANDF":"4018848","INN_ID":"488","RXNORM":"221129","UMLSCUI":"C0028156","chemblId":"CHEMBL572","ChEMBL_ID":"CHEMBL572","KEGG_DRUG":"D00439","DRUGBANK_ID":"DB00698","PDB_CHEM_ID":" U6Z","PUBCHEM_CID":"6604200","SNOMEDCT_US":"373543005","IUPHAR_LIGAND_ID":"10917","SECONDARY_CAS_RN":"54-87-5","MESH_DESCRIPTOR_UI":"D009582"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"present","companyName":"Casper Pharma Llc","relationship":"Current Owner"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"0.97 hours","clearance":"9.7 mL/min/kg","bioavailability":"87%","fractionUnbound":"0.17%","volumeOfDistribution":"0.57 L/kg"},"publicationCount":5045,"therapeuticAreas":["Infectious Disease"],"atcClassification":{"source":"DrugCentral","atcCode":"J01XE01","allCodes":["J01XE01","J01XE51"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 23","pmid":"41892484","title":"Antimicrobial Resistance and ESBL-Associated Predictors Among Uropathogens: A 2019-2024 Isolate-Level Study.","journal":"Antibiotics (Basel, Switzerland)"},{"date":"2026 Feb 25","pmid":"41892400","title":"Evidentiary Standards for Newly Approved Antibiotics for Uncomplicated Urinary Tract Infections.","journal":"Antibiotics (Basel, Switzerland)"},{"date":"2026","pmid":"41886421","title":"Urinary tract infections, risk factors and antimicrobial resistance patterns in heart failure patients on sodium-glucose transporter 2 inhibitors: Evidence from Jakaya Kikwete Cardiac Institute in Tanzania.","journal":"PloS one"},{"date":"2026 Mar 26","pmid":"41885022","title":"Solid Phase Microwave Assisted Synthesis N,S-GQDs as Nano-photocatalyst for Efficient Degradation of Nitrofurantoin and Methylene Blue under Visible Light: Comparative Studies, Mechanism Insight, and Extended Scope.","journal":"Langmuir : the ACS journal of surfaces and colloids"},{"date":"2026","pmid":"41884811","title":"Environmental triggers of autoimmune hepatitis: a clinical perspective from Yemeni patients.","journal":"Frontiers in immunology"}],"combinationProducts":[{"brandName":"Macrobid","ingredients":"nitrofurantoin"},{"brandName":"NITROFURANTOIN MONOHYDRATE MACROCRYSTALLINE","ingredients":"nitrofurantoin"},{"brandName":"Nitrofurantoin","ingredients":"nitrofurantoin"},{"brandName":"Nitrofurantoin Mono","ingredients":"nitrofurantoin"},{"brandName":"Nitrofurantoin Monohydrate/ Macrocrystalline","ingredients":"nitrofurantoin"}],"companionDiagnostics":[],"genericManufacturers":15,"_genericFilersChecked":true,"genericManufacturerList":["Actavis Mid Atlantic","Amneal Pharms","Annora Pharma","Aurobindo Pharma","Biocon Pharma","Chartwell Molecular","Elkins Sinn","Ivax Sub Teva Pharms","Novel Labs Inc","Novitium Pharma","Sandoz","Somerset Theraps Llc","Strides Pharma","Watson Labs","Whiteworth Town Plsn"],"status":"approved","companyName":"Casper Pharma Llc","companyId":"","modality":"Small molecule","firstApprovalDate":"1953","aiSummary":"","enrichmentLevel":4,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1953-02-06T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"1953-02-06T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"1953-02-06T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"1953-02-06T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"1953-02-06T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"1953-02-06T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1988-05-13T00:00:00.000Z","mah":"ALMATICA","brand_name_local":null,"application_number":"NDA016620"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1996-10-15T00:00:00.000Z","mah":"CASPER PHARMA LLC","brand_name_local":null,"application_number":"NDA009175"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2007-06-27T00:00:00.000Z","mah":"ALMATICA","brand_name_local":null,"application_number":"NDA020064"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2021-06-25T00:00:00.000Z","mah":"ALEMBIC","brand_name_local":null,"application_number":"ANDA211935"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2023-11-03T00:00:00.000Z","mah":"OMSAV PHARMA","brand_name_local":null,"application_number":"ANDA217073"},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"Un","currency":"USD","price_amount":"1643.00","price_per":"year","price_type":"NADAC","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":9,"withResults":1},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T00:41:53.869492+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}